Genetics of Sudden Cardiac Death. Geoffrey Pitt Ion Channel Research Unit Duke University. Disclosures: Grant funding from Medtronic.

Similar documents
Preventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete

Strength and weakness of genetic testing in clinical routine.

Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD

Pearls of the ESC/ERS Guidelines 2015 Channelopathies

Prolonged QT Syndromes: Congenital and Acquired

Name of Presenter: Marwan Refaat, MD

Genetic testing in Cardiomyopathies

Ionchannels and channelopaties in the heart. Viktória Szőts

The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes

Sudden Cardiac Death and Asians Disclosures

Genetic Testing for Cardiac Ion Channelopathies

Ionchannels and channelopaties in the heart

Is There a Genomic Basis to Acquired Channelopathic disease

Description. Page: 1 of 31. Genetic Testing for Cardiac Ion Channelopathies. Last Review Status/Date: December 2015

SEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !

Παναγιώτης Ιωαννίδης. Διευθυντής Τμήματος Αρρυθμιών & Επεμβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών

Rhythm and Blues Drugs and QT Prolongation

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Atrial fibrillation in Cardiac Channelopathies

Long QT. Long QT Syndrome. A Guide for Patients

Case studies in Channelopathies

J Wave Syndromes. Osama Diab Lecturer of Cardiology Ain Shams University

Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification

Sudden Unexplained Death in Epilepsy (SUDEP) and Dravet Syndrome

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.

Long Q. Long QT Syndrome. A Guide for

Gene annotation for heart rhythm. 1. Control of heart rate 2. Action Potential 3. Ion channels and transporters 4. Arrhythmia 5.

Genetic Testing for Cardiac Ion Channelopathies. Description

Genetics of Atrial Fibrillation: does it help in treatment decisions?

Noninvasive Predictors of Sudden Cardiac Death

CONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT.

Declaration of conflict of interest. I have nothing to disclose.

3/17/2014. NCDR-14 ICD Registry WS # 24 Case Scenarios Including Syndromes w/ Risk of Sudden Death. Objectives

Inherited Arrhythmia Syndromes

Patient Resources: Cardiac Channelopathies

Silvia G Priori MD PhD

Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada

Wojciech Szczepański, MD, PhD Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division Medical University of Bialystok

ICD in a young patient with syncope

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Hereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases

WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY

Congenital long QT syndrome of particularly malignant course connected with so far unknown mutation in the sodium channel SCN5A gene

Genomics and Cardiac Arrhythmias

Plotse hartdood & genetica

Ventricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC

Protocol. Genetic Testing for Cardiac Ion Channelopathies

Brugada Syndrome: An Update

Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies

Hereditary Conditions Predisposing to Sudden Death

Ion channel dysfunction and diseases of the heart

SUDDEN CARDIAC DEATH(SCD): Definition

SUDDEN CARDIAC DEATH(SCD): Definition

QT Interval: The Proper Measurement Techniques.

Case Demonstrations in Congenital and Acquired Long QT Syndrome

What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment. Andreas Pflaumer

What Every Physician Should Know:

Tailored therapy in long QT syndrome

Genetic Testing for Congenital Long QT Syndrome

Silvia G Priori MD PhD

Phenotypical Manifestations of Mutations in the Genes Encoding Subunits of the Cardiac Sodium Channel

Genetic Testing for Cardiac Ion Channelopathies

Genetic Basis of Ventricular Arrhythmias

Invasive Risk Stratification: When is it needed?

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

The Genetics and Prevention of Sudden Cardiac Death

ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Interpretation and Consequences of Repolarisation Changes in Athletes

Sudden cardiac death (SCD) accounts for 20% of mortality. Sudden Cardiac Death Compendium. Genetics of Sudden Cardiac Death

Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?

Risk Factors for Sudden cardiac Death

Short QT Syndrome: Pharmacological Treatment

Sudden cardiac death: Primary and secondary prevention

Tachycardia Devices Indications and Basic Trouble Shooting

In Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative

Adult Complexities of the Channelopathies

Clinical and Genetic Epidemiology Winter School Personalized Medicine in Cardiology Rhythmology as an Example

Pattarapong Makarawate MD, FHRS Assistant Professor. Division Of Cardiology Faculty of Medicine, Khon Kaen University

Asymptomatic Long QT. Prof. Dr. Martin Borggrefe Mannheim

Molecular Physiology of Ion Channels That Control Cardiac Repolarization

Targeting the late sodium channel: A new antiarrhythmic paradigm?

EVALUATION OF THE ATHLETE. Karen Stout, MD Professor, Medicine and Pediatrics University of Washington

Section: Effective Date: Subsection: Original Policy Date: Subject: Page: Last Review Status/Date: Background

Differences in cardiac atrial and ventricular ion channels

Left cardiac sympathectomy to manage beta-blocker resistant LQT patients

Subcutaneous Implantable Cardioverter Defibrillator (ICD) System

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

Arrhythmias (II) Ventricular Arrhythmias. Disclosures

QUESTION: In a patient with different QT intervals, which one will give the highest prognostic accuracy? REPLY:

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012

J. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam, the Netherlands

Is There A Genetic Basis to Atrial Fibrillation?

Normal heart rhythm requires the finely orchestrated

Cardiac arrhythmias are associated with high morbidity

20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1

Transcription:

Genetics of Sudden Cardiac Death Geoffrey Pitt Ion Channel Research Unit Duke University Disclosures: Grant funding from Medtronic Duke U N I V E R S I T Y

Sudden Cardiac Death High incidence 50-100 per 100 000 in Europe and US 250 000 to 300 000 deaths annually in US More deaths in US than stroke, lung cancer, breast cancer, and HIV AIDS combined Poor survival Overall survival rate 4.6% Often presents without warning or recognized trigger Mean age is in the mid 60s Prediction and Prevention Remain a Challenge

SCD prevention and prediction challenges Limited information about specific triggers 30-40% events are unwitnessed; 95% of victims do not survive Unheralded by symptoms in 40-50% Prog Cardiovasc Dis. 2008; 51:213 80% with high-grade CAD at autopsy, but <5% with known prior CAD

SCD prevention and prediction challenges Non-CAD SCD Inherited rhythm abnormalities, acquired rhythm abnormalities, arrhythmogenic disorders, congenital heart disease, other causes All are substrates for SCD, but SCD only occurs in a minority of subjects Adapted from N Engl J Med 2001;345:1473

Types of non-cad sudden cardiac death Syndromic Inherited arrhythmias (e.g., congenital Long QT Syndrome or Brugada Syndromes) (Arrhythmogenic right ventricular dysplasia) Non-syndromic Population-based QTc changes and risk of SCD Acquired (Drug-induced Long QT Syndrome) and heart failure Arrhythmia = Mutation affecting an ion channel

Ion channels: the basis of the ECG Adapted from Gussak and Antzelevitch (Eds), Electrical Diseases of the Heart

Combined actions of multiple ion channels generate the cardiac action potential Gene Inward DEpolarizing Currents Outward REpolarizing Currents

Syndromic conditions Long QT Syndrome Brugada Syndrome Catecholaminergic Polymorphic Ventricular Tachycardia Short QT Syndrome Arrhythmogenic right ventricular dysplasia Arrhythmia = Mutation affecting an ion channel

Long QT Syndrome

Long QT Syndrome is a channelopathy LOD score = 26

Long QT Syndrome is a channelopathy Type Mutation % LQT1 alpha subunit of the slow delayed rectifier potassium channel (KvLQT1 or KCNQ1) 30-35 LQT2 alpha subunit of the rapid delayed rectifier potassium channel (HERG + MiRP1) 25-30 LQT3 alpha subunit of the sodium channel (SCN5A) 5-10 LQT4 channel anchor protein Ankyrin B <1 LQT5 beta subunit MinK (or KCNE1) which coassembles with KvLQT1 ~1 LQT6 beta subunit MiRP1 (or KCNE2) which coassembles with HERG <1 LQT7 potassium channel KCNJ2 (or Kir2.1) <1 LQT8 alpha subunit of the calcium channel Cav1.2 encoded by the gene CACNA1c <1 LQT9 channel organizing protein caveolin 3 ~1 LQT10 beta subunit SCN4B which coassembles with Nav1.5 (SCN5A) <1 LQT11 channel anchor protein AKAP9 ~1 LQT12 sodium channel regulator SNTA1 ~1 LQT13 alpha subunit of the G protein-activated potassium channel 4 (GIRK4) <1

Long QT Syndrome: channel dysfunction LQT3 Inward DEpolarizing Currents LQT2 LQT1 Outward REpolarizing Currents

Long QT Syndrome: channel dysfunction LQT3 Inward DEpolarizing Currents LQT2 LQT1 Outward REpolarizing Currents

Evolution of LQTS diagnosis Spectrum of reported mutations - 2009 KCNQ1 LQT1 SCN5A LQT3 36% yield overall 75% yield among high probability patients HERG LQT2 missense mutations non-missense mutations Heart Rhythm 2009;6:1297

Not all variants are mutations KCNQ1 LQT1 SCN5A LQT3 6% of normal patients have mutations HERG LQT2 cases rare variants in controls polymorphisms Circulation. 2009;120:1752

Genetic testing especially useful to identify at-risk family members 10-fold increased risk JACC 57, 51, 2011

Brugada Syndrome: channel dysfunction SCN5A mutations account for < 30% of BrS

Brugada Syndrome: channel regulator dysfunction Glycerol-3-phosphate dehydrogenase 1 like LOD score > 4 Circulation 116: 2260, 2007

New Brugada Syndrome loci? LOD scores are low 6% of normal patients have mutations

Non-syndromic conditions Family history of non-cad SCD Inheritability of QT interval Abnormal ECG = Ion channel mutation

Familial risk of SCD in men The Paris Prospective Study I Events in Subjects SCD [n=118] Fatal MI [n=192] Controls [n=6,762] p Parental History of SCD 22 [18.6%] 19 [9.9%] 716 [10.6%] 0.02 Relative Risk 1 affected parent 1.95 [p=.005] 0.97 [p=ns] Relative Risk 2 affected Parents 9.44 [p=.01] Circulation. 1999;99:1978

Many common variants affect QT interval Ion Channels KCNQ1, KCNH2, KCNE1, KCNJ2, SCN5A, SCN10A NOS1AP Ion Channel Regulators NOS1AP, ATP1B1, CASQ2, PLN Others Transcription factors, kinases, and others Nat Genetics 41,399 (2009) Nat Genetics 41,407 (2009) Nat Genetics 42,1068 (2010)

Many common variants affect QT interval Ion Channels KCNQ1, KCNH2, KCNE1, KCNJ2, SCN5A, SCN10A NOS1AP Ion Channel Regulators NOS1AP, ATP1B1, CASQ2, PLN Others Transcription factors, kinases, and others Nat Genetics 41,399 (2009) Nat Genetics 41,407 (2009) Nat Genetics 42,1068 (2010) NOS1AP NOS1AP-1 Hz PNAS 105 4477, 2008 Loss of Function

Abnormal ECG = Mutation affecting an ion channel

Early repolarization and SCD

Acquired conditions Drug-induced LQTS Heart failure Multi-hit hypothesis

% patients with c LQTS locus mutation Drug induced LQTS: an acquired condition with genetic susceptibility QT prolonging drug Circ Arrhythmia Electrophysiol. 2009;2:511

Elevated risk of SCD in heart failure MADIT II SCD-HEFT N Engl J Med 2002; 346:877 N Engl J Med 2005; 352:225

Prolonged QTc in heart failure associated with decreased survival and sudden death DIAMOND study of Dofetilide in heart failure Circulation 2003;107:1764

Not all patients with heart failure have a prolonged QTc: an acquired condition? European Heart Journal (1986) 7, 14

Heart failure, like drug-induced LQTS: A multi-hit hypothesis? Circ. Res. 2004;95;754

SCN5A S1103Y allele is associated with SCD from multiple triggers

Duke EPGEN case-control study Is SCN5A S1103Y associated with appropriate ICD therapy? Ischemic or non-ischemic cardiomyopathy, EF < 35% 112 Primary Prevention ICDs Shock and/or Anti-tachycardia pacing Appropriate ICD Rx 23 89 None / Inappropriate ICD Rx Allele Status at 1103 Allele Status at 1103 Sun et al., Circ: Genetics, in press

Baseline Characteristics Stratified by ICD Therapy Entire Cohort (n=112) Appropriate ICD Therapy (n=23) No Appropriate ICD Therapy (n=89) Characteristic Age, Mean (SD), y 63 (12) 64 (9) 63 (13) Male, No. (%) 74 (66) 18 (78) 56 (63) Medical History Non-Ischemic Cardiomyopathy, No. (%) + 60 (54) 17 (74) 43 (48) Diabetes, No. (%) 57 (51) 11 (46) 46 (52) Tobacco Use, No. (%) 59 (53) 12 (52) 47 (53) Hypertension, No. (%) 101 (90) 22 (96) 79 (89) Hyperlipidemia, No. (%) 81 (72) 18 (78) 63 (71) Atrial Fibrillation, No. (%) 51 (46) 9 (39) 42 (47) NYHA Class, Mean (SD) 2.4 (0.6) 2.3 (0.7) 2.4 (0.6) Ejection Fraction, Mean (SD), % 25 (6) 24 (7) 25 (6) QTc, Mean (SD), ms 464 (41) 463 (45) 465 (40) Serum K + at Enrollment, Mean (SD), mmol/l 4.2 (0.5) 4.1 (0.4) 4.2 (0.5) QT Interval corrected using Bazett s Formula (QTc=QT/ RR) + P=0.03 Sun et al., Circ: Genetics, in press

S1103Y SNP predicts ICD therapy in African Americans with Reduced LVEF Adjusted Hazard Ratio= 4.33 (95% CI 1.60-11.73, p=<0.01) Sun et al., Circ: Genetics, in press

S1103Y SNP predicts ICD therapy in African Americans with Reduced LVEF Adjusted Hazard Ratio= 4.33 (95% CI 1.60-11.73, p=<0.01) Transient Hypokalemia? Sun et al., Circ: Genetics, in press

S524Y SNP does not alter channel function: NOT predictive of ICD therapy P = NS Albert Sun, Patrick Hranitzky

Rates of Sudden Death According to EF VALIANT N Engl J Med 2005;352:2581

Will S1103Y be prognostic fro ICD therapy in African Americans with LVEF >35%? High EF 35% Low EF Incidence of SCD Number of SCD Events

SUMMARY Syndromic conditions Many discovered mutations; not all are pathogenic: effect upon channel function should be validated Several disease gene loci (channel modulators) not yet discovered Non-syndromic/Acquired conditions Manifestations of a genetic predisposition Proof of principle: arrhythmias in heart failure may have a genetic basis Future biomarkers? What are methods for discovery of new loci/biomarkers and subsequent validation?

Fibroblast Growth Factor Homologous Factors (FHFs) FGF11-14 Not secreted Do not bind FGF-Rs Bind to Na + channels Modulate Na + channel function Regulate neuronal excitability FGF14: locus for spinocerebellar ataxia 27 (SCA27) FGF14 -/- mice are ataxic FHFs Function of FHFs in heart - unexplored

FGF13 knockdown affects Na + currents Chuan Wang, Jessica Hennessey

FGF13: a cardiac Na + channel modulator Increases Na + channel availability Accelerates conduction velocity Candidate for an arrhythmogenic locus Loss of function mutations: BrS Molecular, cellular, and animal models useful for analyses of new candidate loci

Acknowledgements Pitt Lab Jessica Hennessey Albert Sun Chaojian Wang Chuan Wang Collaborators Robert Kirkton Nenad Bursac Pat Hranitzky Medtronic-Duke Strategic Alliance